Similarly, opportunities to utilise lncRNAs as biomarkers, vehicles for delivery of therapy and also as therapeutic targets (reviewed in Slack and Chinnaiyan, 2019), in a p53-dependent, or sex-specific manner in cancer remain to be extensively studied. This evidence concerns the gene TP53 and cancer.